Martine Clozel, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland Martine Clozel, a paediatrician specialised in neonatal intensive care, obtained her MD degree at Nancy University, France, and received further training in physiology and pharmacology at McGill University, Montreal, and the University of California, San Francisco. During her 11 years at F. Hoffmann-La Roche Ltd, she initiated the research project on endothelin and endothelin receptor antagonists (ERAs) which led to the discovery and clinical development of bosentan (Tracleer®), tezosentan, clazosentan and other molecules. Her group has published over 130 peer-reviewed papers in the fields of endothelial function, endothelin and ERAs. In 1997, she was awarded the HoffmannLa Roche Research Prize for her achievements in the field of endothelin research. In 1997 she co-founded Actelion Pharmaceuticals Ltd, where she is Senior Vice President and since 2009 Chief Scientific Officer. Martine Clozel is a member of the Scientific Editorial Board of Science Translational Medicine. In 2008, she was honoured as “Chevalier dans l'Ordre de la Légion d'Honneur”.